Actively Recruiting
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
360
Participants Needed
6
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
CONDITIONS
Official Title
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
- Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom
You will not qualify if you...
- Active central nervous system (CNS) involvement unless clinically stable
- History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
- History of solid organ or hematologic stem cell transplantation
- Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
- Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
AdventHealth Orlando
Orlando, Florida, United States, 32803
Actively Recruiting
2
NEXT Oncology
Irving, Texas, United States, 75039
Actively Recruiting
3
Centre Leon Berard
Lyon, France, 69373
Actively Recruiting
4
Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
5
Severance Hospital Yonsei University Health System
Seoul, South Korea, 03722
Actively Recruiting
6
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here